In this episode, we delved into the Life Science space for a conversation with Mark Rohlfing and Natalie Balanovsky from international pharmaceutical business, Almac.
We discussed their new service offering, Almac Adapt and talked about the huge impact it promises to have on the global pharmaceutical market.
We’d love to hear your thoughts on this podcast, and for you to join in the conversation! If you have anything you’d like to add, get in touch at cmconversations@charltonmorris.com
Learn more about Almac Adapt here: https://www.almacgroup.com/clinical-services/almac-adapt-just-in-time-manufacturing-solution/
See Mark on LinkedIn here: https://www.linkedin.com/in/mark-rohlfing-31b49732/
See Natalie on LinkedIn here: https://www.linkedin.com/in/natalie-balanovsky-mba-pmp-87b406b6/
Read our latest content about the Life Science space here: www.searchinglifescience.com
.jpg)
With such a strong 2019, 2020 was expected to be a ‘mega year’ for life science companies with a reported $1.4 trillion in firepower at their disposal for M&As. However, COVID-19 gave us an unexpected twist.
To gain further insight into how labs have adapted, the CM Life Science team spoke to three North American market leaders in laboratory testing services about how they’ve supported the US healthcare system.
There’s so much potential in analytical instrumentation. After a challenging 2020, next year presents itself as a fresh start for the market and these are the companies that you need to keep an eye on.
